Literature DB >> 11107113

Deletion of 11q23 is a frequent event in the evolution of MYCN single-copy high-risk neuroblastomas.

C Guo1, P S White, M D Hogarty, G M Brodeur, R Gerbing, D O Stram, J M Maris.   

Abstract

BACKGROUND: Deletions of the long arm of chromosome 11 are frequently identified in human neuroblastomas. PROCEDURE: We screened 394 primary neuroblastomas and 52 tumor-derived cell lines with a panel of 11q and 11p polymorphic markers to determine the frequency of chromosome 11 allelic deletion, and to differentiate partial deletions of chromosome 11q (unb[11q] LOH) from whole chromosome loss.
RESULTS: Allelic deletion occurred most frequently at cytogenetic band 11q23 and was detected in 161 primary neuroblastomas (41%) and 18 cell lines (35%). Eighty-seven tumors (22%) had unb[11q] LOH with a heterogeneous distribution of deletion breakpoints. Unb[11q] LOH was highly correlated with age > 1 year at diagnosis (P = 0.008), stage 4 disease (P = 0.001), unfavorable Shimada histopathology (P < 0.001), and assignment to a high-risk therapeutic protocol (P < 0.001), and was inversely correlated with MYCN amplification (P = 0.018). Patients whose tumors showed unb[11q] LOH were less likely to survive (P < 0.001), but there was only a trend towards an independent prognostic influence in multivariate analyses.
CONCLUSIONS: Thus, structural rearrangements resulting in unb[11q] LOH commonly occur during the malignant evolution of high-risk neuroblastomas with single-copy MYCN. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2000        PMID: 11107113     DOI: 10.1002/1096-911x(20001201)35:6<544::aid-mpo10>3.0.co;2-2

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  11 in total

1.  2p24 Gain region harboring MYCN gene compared with MYCN amplified and nonamplified neuroblastoma: biological and clinical characteristics.

Authors:  Marta Jeison; Shifra Ash; Gili Halevy-Berko; Jacques Mardoukh; Drorit Luria; Smadar Avigad; Galina Feinberg-Gorenshtein; Yacov Goshen; Gabriel Hertzel; Joseph Kapelushnik; Ayelet Ben Barak; Dina Attias; Ran Steinberg; Jerry Stein; Batia Stark; Isaac Yaniv
Journal:  Am J Pathol       Date:  2010-04-15       Impact factor: 4.307

Review 2.  Neuroblastoma tumour genetics: clinical and biological aspects.

Authors:  N Bown
Journal:  J Clin Pathol       Date:  2001-12       Impact factor: 3.411

3.  Association between glioma susceptibility loci and tumour pathology defines specific molecular etiologies.

Authors:  Anna Luisa Di Stefano; Victor Enciso-Mora; Yannick Marie; Virginie Desestret; Marianne Labussière; Blandine Boisselier; Karima Mokhtari; Ahmed Idbaih; Khe Hoang-Xuan; Jean-Yves Delattre; Richard S Houlston; Marc Sanson
Journal:  Neuro Oncol       Date:  2012-11-16       Impact factor: 12.300

4.  Region-specific detection of neuroblastoma loss of heterozygosity at multiple loci simultaneously using a SNP-based tag-array platform.

Authors:  John M Maris; George Hii; Craig A Gelfand; Shobha Varde; Peter S White; Eric Rappaport; Saul Surrey; Paolo Fortina
Journal:  Genome Res       Date:  2005-08       Impact factor: 9.043

5.  Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma.

Authors:  Shahab Asgharzadeh; Jill A Salo; Lingyun Ji; André Oberthuer; Matthias Fischer; Frank Berthold; Michael Hadjidaniel; Cathy Wei-Yao Liu; Leonid S Metelitsa; Roger Pique-Regi; Peter Wakamatsu; Judith G Villablanca; Susan G Kreissman; Katherine K Matthay; Hiroyuki Shimada; Wendy B London; Richard Sposto; Robert C Seeger
Journal:  J Clin Oncol       Date:  2012-08-27       Impact factor: 44.544

6.  Bioinformatics analysis of recurrent deletion regions in neuroblastoma.

Authors:  Hasan Onur Caglar
Journal:  Med Oncol       Date:  2022-01-20       Impact factor: 3.064

7.  Positional and functional mapping of a neuroblastoma differentiation gene on chromosome 11.

Authors:  Katleen De Preter; Jo Vandesompele; Björn Menten; Philippa Carr; Heike Fiegler; Anders Edsjö; Nigel P Carter; Nurten Yigit; Wim Waelput; Nadine Van Roy; Scott Bader; Sven Påhlman; Frank Speleman
Journal:  BMC Genomics       Date:  2005-07-06       Impact factor: 3.969

8.  Neuroblastomas with chromosome 11q loss and single copy MYCN comprise a biologically distinct group of tumours with adverse prognosis.

Authors:  M E Luttikhuis; J E Powell; S A Rees; T Genus; S Chughtai; P Ramani; J R Mann; C M McConville
Journal:  Br J Cancer       Date:  2001-08-17       Impact factor: 7.640

9.  Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification.

Authors:  Zhi-Xia Yue; Tian-Yu Xing; Chao Gao; Shu-Guang Liu; Wen Zhao; Qian Zhao; Xi-Si Wang; Mei Jin; Xiao-Li Ma
Journal:  Cancer Commun (Lond)       Date:  2019-11-04

10.  No evidence for involvement of SDHD in neuroblastoma pathogenesis.

Authors:  Katleen De Preter; Jo Vandesompele; Jasmien Hoebeeck; Caroline Vandenbroecke; Jöel Smet; Annick Nuyts; Geneviève Laureys; Valérie Combaret; Nadine Van Roy; Frank Roels; Rudy Van Coster; Marleen Praet; Anne De Paepe; Frank Speleman
Journal:  BMC Cancer       Date:  2004-08-24       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.